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Abstract
Background: Osteogenesis imperfecta (OI) is a rare bone disorder. In 90% of cases, OI is caused by mutations in
the COL1A1/2 genes, which code procollagen α1 and α2 chains. The main aim of the current research was to
identify the mutational spectrum of COL1A1/2 genes in Estonian patients. The small population size of Estonia
provides a unique chance to explore the collagen I mutational profile of 100% of OI families in the country.
Methods: We performed mutational analysis of peripheral blood gDNA of 30 unrelated Estonian OI patients using
Sanger sequencing of COL1A1 and COL1A2 genes, including all intron-exon junctions and 5′UTR and 3′UTR regions,
to identify causative OI mutations.
Results: We identified COL1A1/2 mutations in 86.67% of patients (26/30). 76.92% of discovered mutations were
located in the COL1A1 (n = 20) and 23.08% in the COL1A2 (n = 6) gene. Half of the COL1A1/2 mutations appeared
to be novel. The percentage of quantitative COL1A1/2 mutations was 69.23%. Glycine substitution with serine was
the most prevalent among missense mutations. All qualitative mutations were situated in the chain domain of pro-
α1/2 chains.
Conclusion: Our study shows that among the Estonian OI population, the range of collagen I mutations is quite
high, which agrees with other described OI cohorts of Northern Europe. The Estonian OI cohort differs due to the
high number of quantitative variants and simple missense variants, which are mostly Gly to Ser substitutions and
do not extend the chain domain of COL1A1/2 products.
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Background
Despite being a rare genetic bone fragility disorder,
osteogenesis imperfecta (OI) is among the most widely
occurring of rare congenital skeletal dysplasias [1]. OI
prevalence is estimated 1/10,000–20,000 at birth [2, 3]. OI
is characterized by low bone mineral density, recurrent
fractures, skeletal deformations, and blue eye sclera [2, 4–
6]. Other remarkable features of OI include Dentinogen-
esis Imperfecta, triangular face, hearing loss, joint laxity,
short stature, and easy bruising [2, 4–6].
OI has many manifestations and is considered a group
of disorders. Phenotypes range from mild osteopenia to
severe deformities or even mortality. In 1979, Sillence
described four OI types (I–IV) according to phenotype
severity [5]. Recent updated classification distinguishes
three additional types with specific histologies (V–VII)
[4, 7]. Genetic OI classification considers every OI gene
as a separate OI type and so far includes OI types
I–XVII [4, 8, 9].
The genetics of the disorder reflect the complexity of
the OI phenotype range. Up to 21 different genes have
been associated with occurrence of OI [10–19]. Previous
studies have shown that the primary cause of OI are
mutations in the COL1A1/2 genes, which code procolla-
gen type I α1 and α2 chains, respectively [20]. Despite
the approximately 1500 mutations already described in
collagen type I genes, investigators continue to report
novel mutations [21]. Moreover, there is still some
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controversy regarding the proportion of collagen mu-
tations reported in different populations, which have
ranged from 60 to 95% [9, 10]. In this context, we
believe that population-based studies of OI genetics
might broaden current knowledge of collagen I muta-
tions and OI.
Due to Estonia’s small population (1.3 million) and
centered treatment, follow-up, and research of all OI pa-
tients at the OI Center of the Traumatology and Ortho-
pedics Clinic, Tartu University (TU) Hospital, it was
possible to perform analysis of COL1A1/2 mutations
among the whole Estonian OI population [22]. Herein,
we describe for the first time the mutational spectrum of
COL1A1/2 genes among 30 unrelated OI patients, from
30 Estonian OI families, which we estimate to constitute
~ 100% of OI cases in Estonia.
Methods
Subjects
The patients included in the study are treated and
followed-up by the OI Center of the Traumatology and
Orthopedics Clinic, TU Hospital.
A total of 30 OI patients from 30 unrelated families
were included in the study. Data regarding the OI types
of the subjects were obtained from the medical records
of TU Hospital [23]. All new OI cases across Estonia are
registered by and treated at TU Hospital’s OI Center.
Thus, it can be estimated that as of May 2017, the
current patient cohort represented ~ 100% of the Esto-
nian OI population.
No patient came from a consanguineous family. Muta-
tional analysis of the COL1A1/2 genes was performed
on a younger affected member of every OI family in-
cluded in the study.
In accordance with the Declaration of Helsinki, all pa-
tients or their legal representatives signed an informed
consent form prior to participation. The study was ap-
proved by the University of Tartu’s Ethical Review Com-
mittee on Human Research (permit no. 221/M-34).
Genealogical description
Genealogical data of OI history in the family, consan-
guinity, and miscarriages was obtained from each pa-
tient or their representative. We constructed pedigree
trees per kindred using the “Kinship2” package in R
v3.3.2 [24].
Mutational analysis of the COL1A1/2 genes
Genomic DNA (gDNA) was purified from 3 ml of
ethylenediaminetetraacetic acid (EDTA) preserved whole
blood samples—stored at −80 °C—using a Gentra Pure-
gene Blood Kit (Quiagen, Germany) following the manu-
facturer’s protocol.
PCR amplification and Sanger sequencing were per-
formed as described previously [25]. Sequence products
were analyzed using Applied Biosystems’ Sequence Scan-
ner v1.0 and Mutation Surveyor DNA Variant analysis
software v5.0.1. (Softgenetics, USA) and aligned to the
GenBank human reference genome sequences of
COL1A1 (gDNA NG_007400.1, complementary (cDNA)
NM_000088.3), and COL1A2 (gDNA NG_007405.1,
cDNA NM_000089.3). Raw sequencing data are available
from the authors upon request. We focused on non-
synonymous and splice-site variants absent from the
publicly available normal datasets (including dbSNP135
and the 1000 Genomes Project) [26, 27]. We used the
PolyPhen-2, SIFT, and MutationTaster software tools to
predict the functional effects and pathogenicity of muta-
tions [28–30]. Variants absent from the osteogenesis
imperfecta mutation database were considered novel
(http://www.le.ac.uk/ge/collagen/) [21, 31].
All statistical analyses were carried out with R v3.3.2.
software (R Team, Austria) [32]. To assess the distribu-
tion of COL1A1/2 mutations and compare them to other
studied OI populations, percentage differences were
used.
Results
Mutational analysis of the COL1A1/2 genes of Estonian
OI patients highlighted OI causative mutations in 26 of
30 patients (86.67%) (Fig. 1a). The number of patients
harboring COL1A1 mutations was 20 (76.92%); COL1A2
mutations were found in 6 patients (23.08%) (Fig. 1b). A
list of the mutations and their characteristics can be
found in Table 1.
The number of novel mutations was 13/26 (50%) (Table
1). Half of the COL1A1 and COL1A2 mutations appeared
to be undescribed in the collagen type I mutation data-
base. Patient EE26 had a heterozygous non-synonymous
rs1800215 SNP (p.Ala1075Thr) in the COL1A1 gene,
which was described before as a benign variant (data not
shown). [33]
Twenty-five mutations had an autosomal dominant in-
heritance pattern (Table 1). Of these, eight patients had
no previous history of OI in the family. Thus, we
assumed that their parents and relatives, who did not
have any clinical features of OI, are not carriers of these
mutations.
Patient EE07 had a recessive missense mutation.
Mutational analysis showed that their parents are not
carriers of the mutation, which confirmed the de novo
nature of the mutation.
We found 12/26 mutations (46.15%) had altering
splice sites, 10 and 2 in the COL1A1 and COL1A2 genes,
respectively. One of the patients harbored a deletion
capturing both coding and intronic sequence, in exon-
intron 34 (EE30). Nonsense mutations were present in 6
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patients (23.08%), all in the COL1A1 gene. Overall,
quantitative mutations were present in 18 patients (16 in
COL1A1 and 2 in COL1A2 genes) (Fig. 2).
Missense mutations, associated with collagen I quality
defects, were indicated in eight patients (30.77%), four in
COL1A1 and four in COL1A2 genes. Of these, seven
were Glycine substitutions (four of the COL1A2 and
three of the COL1A1 missense mutations). In four cases,
Glycine was substituted with Serine, two in the COL1A1
and COL1A2 genes, respectively (Fig. 2).
A c.3262G>T (COL1A1) mutation was detected in two
patients (EE21 and EE22), who were thought to be unre-
lated (Table 1). Investigation of the pedigree trees
revealed a distant relationship between the families four
generations back, of which the patients were not aware.
Two identical splice site mutations at c.1821 + 1G>A
(COL1A1) in intron 26 were identified in patients EE02
(type III OI) and EE05 (type I OI) (Table 1). This muta-
tion arose independently in the patients and caused phe-
notypes of different severity.
Discussion
Collagen I mutations were found in 26/30 (87%) studied
OI patients. Previous findings have suggested collagen
mutations ranging from 60 to 90% among different OI
populations and study cohorts [25]. In a Finnish OI
study, 90.7% of patients harbored collagen I mutations
[34], which is higher than we found among Estonian OI
patients. In Pollitt et al.’s study, collagen I mutations
were revealed in 75% of OI patients [35], which is
slightly lower than our Estonian cohort. Our data is in
good agreement with research on the genetic epidemi-
ology of the Swedish OI population, of which 87% had
collagen I mutations [36]. The results of our study are
also in concordance with Bardai et al.’s recent study of a
large number (598) of OI individuals, where collagen
type I mutations were found in 86% of OI patients of all
types and different ethnic groups [19].
In some population studies, the amount of collagen I
mutations were also lower. For example, in 51.4% of Tai-
wanese patients (N = 72), 52.2% of Korean patients
(N = 67), and 59.4% of Vietnamese OI patients (N = 91)
[25, 37, 38]. Due to the difficulties in arranging large
cross-population studies of a rare disorder in populous
countries, results can often be fragmented, which com-
plicates population-wide estimates [39, 40]. However,
questions about the lower collagen type I mutational
pattern of OI patients from Asian populations remain.
The proportions of COL1A1 and COL1A2 in Estonian,
Finnish, and Swedish OI populations were surprisingly
similar, 77 and 23%, 78 and 22%, and 79 and 21%, re-
spectively [34, 36]. Similar values were reported by Pol-
litt et al., where 77% of mutations occurred in the
COL1A1 and 23% in the COL1A2 gene (N = 83) [35]. In
a
b
Fig. 1 Diagram of collagen type I mutation distribution Estonian OI patients. a Percentage of patients with COL1A1/2 mutations vs patients
negative for collagen I mutations. b Percentage of mutations in the COL1A1 and COL1A2 genes
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Bardai et al.’s 2016 study, 69% were COL1A1 and 31%
COL1A2 mutations, which is similar to the beforemen-
tioned results [19].
The Estonian cohort also has a high proportion of
quantitative mutations compared to qualitative collagen
mutations, 69 and 31%, respectively. In the Finnish OI
cohort, 67% of mutations were quantitative and 33%
qualitative [34]. In the work of Pollitt et al., 35% of
mutations were qualitative and 65% quantitative [35]. In
the Swedish population, the proportions were almost
equal (53 and 47%) [36]. Interestingly, we found only
two quantitative mutations in the COL1A2 gene, which
matches previous reports about comparatively lower
numbers of quantitative mutations of this gene [34–36].
Due to the higher number of mutations leading to
haploinsufficiency in the COL1A1 gene compared to the
COL1A2 gene, patients harboring mutations in the
COL1A1 gene had milder phenotypes (I, IV) compared
to patients with COL1A2 mutations (type III, except
EE20 who had a splice site mutation and OI type I).
Glycine substitutions composed the vast majority of
missense mutations (7 of 8 cases), with serine being the
most substituted amino acid (4 of 7 cases), which
supports previous findings. Curiously, all missense
mutations were situated in triple helical chain domains
(aa residues 162–1218 α1; aa residues 80–1102 α2) of
COL1A1/2 gene products. Only one mutation (patient
EE07 with OI type II) altered the “lethal cluster” pro-
posed by Marini et al. [41].
Half of the mutations (50%) we found appeared to be
novel. Despite the numerous works on collagen I muta-
tions and a growing list of identified mutations, the num-
ber of revealed novel variants was high, which underlines
the individual nature of OI mutations [19, 35, 36]. Half of
the glycine substitutions (4 of 7) were even absent from
the collagen I mutational database.
Table 1 Mutational spectrum of the COL1A1 and the COL1A2 genes among Estonian OI patients
No Patient ID Gene Mutation Exon Mutation type Protein alteration Sillence OI type
1 EE01# COL1A2 c.1630G>GT* Exon 28 Missense p.Gly544Cys III
2 EE02 COL1A1 c.1821 + 1G>GA Intron 26 Splice site – III
3 EE03 COL1A1 c.1897G>GT* Exon 26 Nonsense p.Glu633* IV
4 EE04 COL1A1 c.750 + 2T>TA* Intron 10 Splice site – IV
5 EE05 COL1A1 c.1821 + 1G>GA Intron 26 Splice site – I
6 EE07# COL1A1 c.2317G>T* Exon 33_34 Missense p.Gly773Cys II
7 EE08 COL1A1 c.3217G>GA* Exon 45 Missense p.Gly1073Ser III
8 EE09 COL1A1 c.1155 + 2T>TG* Intron 17 Splice site – I
9 EE10 COL1A1 c.1128_hetdelT Exon 17 Frameshift p.Gly377Alafs*164 I
10 EE11# COL1A1 c.3235G>GA Exon 45 Missense p.Gly1079Ser I
11 EE13 COL1A1 c.2089C>CT Exon 31 Nonsense p.Arg697* IV
12 EE14# COL1A1 c.904-9G>GA Intron 13 Splice site – I
13 EE15 COL1A2 c.1009G>GA Exon 19 Missense p.Gly337Ser III
14 EE16# COL1A2 c.2324G>GA Exon 38 Missense p.Gly775Glu III
15 EE17# COL1A1 c.3045 + 1G>GA Intron 42 Splice site – IV
16 EE18 COL1A1 c.505G>GA* Exon 6 Missense p.Glu169Lys I
17 EE19 COL1A1 c.299-1G>GC* Intron 3 Splice site – IV
18 EE20 COL1A2 с.937-3С>CT Intron 18 Splice site – I
19 EE21 COL1A1 c.3262G>GT* Exon 46 Nonsense p.Gly1088* IV
20 EE22 COL1A1 c.3262G>GT* Exon 46 Nonsense p.Gly1088* I
21 EE24 COL1A1 c.1767 + 5G>GA* Intron 25 Splice site – IV
22 EE25 COL1A1 c.1354-2A>AG Intron 20 Splice site – I
23 EE27# COL1A1 c.3208-1G>GA* Intron 44 Splice site – I
24 EE29# COL1A2 c.865G>AG Exon 17 Missense p.Gly289Ser III
25 EE30 COL1A2 c.2026-1_2031het dup* Intron-Exon 34 Splice site, frameshift – III/IV
26 EE31# COL1A1 c.1081C>CT Exon 17 Nonsense p.Arg361* I
Patients with de novo mutations and without OI history in the family are marked with an octothorp (#). Novel mutations unreported in the collagen type I variant
database (http://www.le.ac.uk/ge/collagen/) are marked with an asterisk (*). In cases of heterozygous mutation, both the wild type and the mutated allele are
indicated after an arrow (>)
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Despite sharing of the same mutation, patients may
develop different phenotypes, as in the case of patients
EE02 and EE05, who had type III and I OI, respectively.
Genotype-phenotype correlations remain an unresolved
issue in our understanding of OI. Cases of inter- and
intra-familial OI diversity are not rare. Not only genetics,
but additional factors, such as epigenetics and environ-
ment might contribute to the development of specific
OI phenotypes. This leads to many questions and the
need to further investigate potential OI factors.
Sanger sequencing is a powerful and accurate method
of mutational analysis and allows the identification of
frameshift, and missense and nonsense mutations in the
coding regions of genes. Moreover, due to the special
design of the primers distant from intron-exon junction
regions, we could asses splice site mutations of the
COL1A1/2 genes, which are the cause of quantitative
collagen defects. However, the current study had some
limitations. We could not identify whole gene or exon
deletions and duplications, which could have slightly
reduced the number of discovered COL1A1/2 mutations.
In addition, due to the small population size of Estonia,
our cohort was limited. We cannot exclude the possibil-
ity that the small sample size might be the cause of
differences compared to the results of other studies.
Conclusion
This paper has described the mutational spectrum of
COL1A1/2 genes among 30 Estonian OI patients, which
were estimated to represent ~ 100% of OI families in
Estonia at the time. We identified collagen I mutations
in 87% of Estonian OI families. The number of
a
b
c
Fig. 2 a Mutational spectrum of COL1A1/2 mutations in Estonian OI patients. Distribution of the COL1A1 (b) and COL1A2 (c) mutations according
to mutation type
Zhytnik et al. Human Genomics  (2017) 11:19 Page 5 of 7
quantitative mutations (69%) was high compared to
other European OI cohorts. All missense mutations of
our Estonian patients altered the triple helical chain do-
main of α1 and α2 procollagen chains. One mutation
was situated in the lethal cluster. A normal distribution
of novel collagen mutations (50%) among the COL1A1
(77%) and COL1A2 (23%) genes, and mostly glycine sub-
stitutions were observed, compared to other OI cohorts
of Northern Europe. Four patients that showed no colla-
gen type I mutations will be further studied using whole
exome sequencing analysis to identify disease causing
variants.
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